Research on the post-marketing surveillance of rivaroxaban found that the drug was as safe as determined from the results of the anticoagulant’s randomized controlled trial.
Research on the post-marketing surveillance of rivaroxaban found that the drug was as safe as determined from the results of the anticoagulant’s randomized controlled trial.
A poster presented at the European Society of Cardiology's annual congress in London looked at almost 40,000 people taking rivaroxaban after it was approved by the FDA to determine how often they bled and what the consequences were, explained W. Frank Peacock IV, MD, from the Baylor College of Medicine, in a video interview with MD Magazine.
“When you have a randomized controlled trial, you have a very refined population of people with a certain age and a certain risk factor profile that is well described,” he said. “When you roll out to the public and all doctors anywhere can use it, you’re not always certain they’re going to apply it right and that risk-benefit analysis may change.”
He added that sometimes when a drug is rolled out to the public, there are “strange little things” that happen. In the case of this study, that did not occur.
“We wanted to make sure that the results that we had in real life look like the results that we had when we studied it in a randomized controlled trial,” Dr Peacock said.
The study found that of the nearly 40,000 people in the study, 970 had a bleed and most of them had a gastrointestinal bleed. In addition, 35 people died, mostly from intracranial hemorrhages. Dr Peacock added that the bleed rate was about 2.89 for 100 patient years and the risk of dying was 0.1.
“This is all statistically consistent with what we saw in the trials and it goes to show you that these drugs are inherently safe,” he said.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More